Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

T-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documented favorable safety profile and efficacy in terms of SARS-CoV-2-specific T-cell response. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Heitmann, Jonas S., Tandler, Claudia, Marconato, Maddalena, Nelde, Annika, Habibzada, Timorshah, Rittig, Susanne M., Tegeler, Christian M., Maringer, Yacine, Jaeger, Simon U., Denk, Monika, Richter, Marion, Oezbek, Melek T., Wiesmüller, Karl-Heinz, Bauer, Jens, Rieth, Jonas, Wacker, Marcel, Schroeder, Sarah M., Hoenisch Gravel, Naomi, Scheid, Jonas, Märklin, Melanie, Henrich, Annika, Klimovich, Boris, Clar, Kim L., Lutz, Martina, Holzmayer, Samuel, Hörber, Sebastian, Peter, Andreas, Meisner, Christoph, Fischer, Imma, Löffler, Markus W., Peuker, Caroline Anna, Habringer, Stefan, Goetze, Thorsten O., Jäger, Elke, Rammensee, Hans-Georg, Salih, Helmut R., Walz, Juliane S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439231/
https://www.ncbi.nlm.nih.gov/pubmed/37596280
http://dx.doi.org/10.1038/s41467-023-40758-0

Ejemplares similares

Ejemplares similares